News Jiangsu Kanion Pharmaceutical Co.,Ltd.

Equities

600557

CNE000001CL7

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
18.87 ^CNY	+1.89%		+0.27%	-8.04%

Apr. 12	Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 12	CI
Tranche Update on Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 01	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 10	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	Feb. 06	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	Feb. 05	CI
Kanion Pharmaceutical's Jinzhen Oral Liquid Shows Positive Result in Clinical Trial	Dec. 08	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd.(XSSC:600557) added to S&P Global BMI Index	23-09-18	CI
Kanion Pharmaceutical Gets Clinical Trial Nod in China for Pain Medicine	23-09-11	MT
Kanion Pharmaceutical Wins Chinese Drug Regulator's Nod to Trial Wubie Huangui Granules	23-09-04	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-12	CI
Kanion Pharma Wins FDA Nod to Trial Myeloma Treatment Candidate in US	23-06-27	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-07	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-20	CI
Kanion Pharma’s Common Cold Drug Included in China’s Medical Insurance Catalog	23-01-19	MT
Jiangsu Kanion Pharma Gets Nod for Anti-Cancer Injection Trial	23-01-11	MT
Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registration	22-12-30	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-09	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jiangsu Kanion Pharmaceutical Co.,Ltd.

Equities

600557

CNE000001CL7

Summary

Filters